趋化素与阻塞性睡眠呼吸暂停低通气综合征患者咽部脂肪沉积的相关性
Chemerin in Obstructive Sleep Apnea-hypopnea Patients' Pharyngeal Fat Deposition
-
摘要: 目的 比较阻塞性睡眠呼吸暂停低通气综合征 (obstructive sleep apnea-hypopnea syndrome, OSAHS) 患者与非打鼾者的咽部脂肪趋化素水平, 分析趋化素对OSAHS患者咽部脂肪沉积的影响.方法 以OSAHS住院的患者作为实验组, 非打鼾的慢性扁桃体炎患者作为对照组, 行多导睡眠监测并检测腭帆间隙脂肪组织趋化素水平, 并对比2组代谢综合征相关指标, 分析趋化素与上述因子之间的相关性.结果 OSAHS患者腭帆间隙脂肪组织中趋化素水平高于非打鼾组, 且与TG、HOMA-IR和尿酸水平等指标呈正相关.OSAHS患者的代谢综合征指标与对照组之间差异有统计学意义 (P<0.05) .结论 OSAHS患者咽部脂肪中趋化素水平高于对照组, 且与代谢综合征指标呈正相关.趋化素可能参与了OSAHS患者咽部脂肪沉积过程, 并与代谢综合征途径有关.
-
关键词:
- 阻塞性睡眠呼吸暂停低通气综合征 /
- 趋化素 /
- 代谢综合征
Abstract: Objective To analyze the effect of chemerin on the pharyngeal fat deposition by comparing the level of chemerin of fat tissue in pharynx between the patients with OSAHS and non-snorer. Methods OSAHS patients finished PSG and non-snoring patients with tonsillitis as controlled group were examined to observe their chemerin level of space veli palatine. Comparisons of the chemerin level and the indexes of MS were made to analyze the relationship between chemerin and MS. Results The level of chemerin of space veli palatine in OSAHS patients was higher than that of the control groups. And the level of chemerin within the OSAHS patients also had positive correlation with TG、HOMA-IR and uric acid. We also found that the TG, HDL-C, FINS, HOMA-IR and the uric acid had statistical differences (P <0.05) between the two groups. Conclusion The level of chemerin of OSAHS group is exceed the control group and positively related with indexes of MS. Chemerin may take part in the development of fat deposition in pharynx of OSAHS patients, which may be through MS pathway.-
Key words:
- Obstructive sleep apnea-hypopnea syndrome /
- Chemerin /
- Metabolic Syndrome
-
[1]施斌, 吴海莺, 白忠.趋化素与阻塞性睡眠呼吸暂停低通气综合征相关性的研究进展[J].海南医学, 2017, 28 (6) :951-954. [2]中华医学会耳鼻咽喉头颈外科学分会咽喉学组.阻塞性睡眠呼吸暂停低通气综合征诊断和外科治疗指南[J].中华耳鼻咽喉头颈外科杂志, 2009, 44 (2) :95-96. [3] [3]OUCHI N, PARKER J L, LUGUS J J, et al.Adipokines in inflammation and metabolic disease[J].Nat Rev Immunol, 2011, 11 (2) :85-97. [4] [4]POULOS S P, HAUSMAN D B, HAUSMAN G J.The development and endocrine functions of adipose tissue[J].Mol Cell Endocrinol, 2010, 323 (1) :20-34. [5] [5]NAGPAL S, PATEL S, JACOBE H, et al.Tazarotene-induced gene 2 (TIG2) , a novel retinoid-responsive gene in skin[J].J Invest Dermatol, 1997, 109 (1) :91-95. [6] [6] BOZAOGLU K, BOLTON K, MCMILLAN J, et al.Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J].Endocrinology, 2007, 148 (10) :4687-4694. [7] [7]ISSA M E, MURUGANANDAN S, ERNST M C, et al.Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis[J].Am J Physiol Cell Physiol, 2012, 302 (11) :C1621-1631. [8] [8]TAKAHASHI M, OKIMURA Y, IGUCHI G, et al.Chemerin regulates beta-cell function in mice[J].Sci Rep, 2011, 1 (11) :123. [9] [9]GORALSKI K B, MCCARTHY T C, HANNIMAN E A, et al.Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism[J].J Biol Chem, 2007, 282 (38) :28175-2888. [10] [10]ERNST M C, SINAL C J.Chemerin at the crossroads of inflammation and obesity[J].Trends Endocrinol Metab, 2010, 21 (11) :660-667. [11] [11]SELL H, LAURENCIKIENE J, TAUBE A, et al.Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells[J].Diabetes, 2009, 58 (12) :2731-2740. [12] [12]GU P, JIANG W, LU B, et al.chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients[J].Clin Exp Hypertens, 2014, 36 (5) :326-332. [13] [13]BOZAOGLU K, BOLTON K, MCMILLAN J, et al.Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J].Endocrinology, 2007, 148 (10) :4687-4694. [14] [14]BADRAN M, AYAS N, LAHER I.Insights into obstructive sleep apnea research[J].Sleep Med, 2014, 15 (5) :485-495.
点击查看大图
计量
- 文章访问数: 1971
- HTML全文浏览量: 687
- PDF下载量: 61
- 被引次数: 0